GA_P advises Uriach on the sale of its generics and b2b business to MCH

Gómez-Acebo & Pombo has advised Grupo J. Uriach on the sale of its B2B business to the investment fund MCH, with the participation of a group of investors. With this transaction, Uriach completes the process of divestment in the pharmaceutical sector and sale of generics, to focus on its strategic business plan in the Consumer Healthcare (CHC) sector.

The divestment involves the sale of the two production plants owned by Grupo J. Uriach Group in Spain. On the one hand, the chemical plant (Urquima) located in Sant Fost de Campsentelles and the pharmaceutical plant in Palau-Solità i Plegamans, which currently allocates 75-80% of its production to the B2B business. The rest of this production is dedicated to CHC, which will continue to be made at this plant through a long-term strategic production agreement between Grupo J. Uriach and the new company owned by the new company. Uriach Group and the new company owned by MCH. This area has a forecast turnover of 80 million by the end of 2021. MCH’s objective is to expand its activity through new developments and R&D investment.

The sale agreement is currently subject to the approval of the competition authorities.

Lazard has been the bank advisor leading the transaction and Deloitte has acted as financial advisor.

The GA_P team was formed by Dani Marín, Carolina Posse, Estefanía Fraile and Diana Urrego, partner and associate, respectively, in the Corporate area, Iñigo Igartua and Andrea Díez de Uré, partner and associate in the Competition area, Nuria Vila, of counsel in the Tax area and Begoña Vilar, associate in the Employment area.

See complete article in Cinco Días